Alphamab Licences First-in-Class TROP2×HER3 ADC to Pathos

China-based Alphamab Oncology has announced that its subsidiary Jiangsu Alphamab granted Pathos AI exclusive ex-Greater China rights to JSKN016, a first-in-class TROP2×HER3 bispecific antibody–drug conjugate (ADC) built on the company's single-domain antibody and glycan-site-specific conjugation platforms with a homogeneous DAR4 payload of a topoisomerase I inhibitor. JSKN016 is already in multiple Phase II studies across lung and breast cancers, with a Phase III trial underway in triple-negative breast cancer (TNBC), and is designed to block oncogenic signalling while delivering targeted cytotoxic release with reduced off-target toxicity.

The transaction carries USD 125 million upfront, up to USD 2.093 billion in aggregate development and commercial milestones, and high-single to low-double-digit percentage royalties on ex-China net sales, with Pathos bearing all development and commercialisation costs. Alphamab retains full rights in Mainland China, Hong Kong, Macau, and Taiwan, and receives a warrant to subscribe for USD 62.5 million of Pathos preferred shares at its discretion.

The deal extends Alphamab's ADC out-licensing track record and positions JSKN016 as a differentiated dual-target entrant against single-target TROP2 assets such as datopotamab deruxtecan.

Daily News
GSK's Bepirovirsen Becomes First Approved Functional Cure for CHB
2026-08-25
Global Biotech Funding Rebounds 103% YoY in Q2'26, Driving CXO Demand
2026-08-25
BI Halts Phase I Trial of ADHD Asset After Safety Event
2026-08-24
Genentech Licences Hanmi's CRHR2 Urocortin Analogue for Up to USD 2.3bn
2026-08-24
Qilu's KRAS G12D Inhibitor Shows 78.6% DCR in NSCLC Phase I
2026-08-24
Latest Report
2026 TOP-25 Drug Targets
Details